Shares of IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, rose in the fourth quarter on better-than-expected earnings and progress on moving to a direct distribution model in the U.S. IDEXX’s fundamentals continue to improve, with organic growth in its core business reaching 12% in the most recently reported quarter. We believe organic revenue growth at current levels is sustainable due to recent innovations in IDEXX’s portfolio of diagnostic products, instruments, data management tools, and geographic expansion. (Rebecca Ellin)
From Ron Baron (Trades, Portfolio)'s Baron Partners Fund Fourth Quarter 2014 Commentary.
